S-268019 (Ukrainian Wikipedia)

Analysis of information sources in references of the Wikipedia article "S-268019" in Ukrainian language version.

refsWebsite

Global rank Ukrainian rank

4^th place

5^th place

2^nd place

4^th place

low place

5,225^th place

4,744^th place

clinicaltrials.gov

Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H (липень 2022). Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Vaccine. 40 (31): 4231—4241. doi:10.1016/j.vaccine.2022.05.081. PMC 9167832. PMID 35691872. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)
Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M (червено 2022). Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 40 (27): 3721—3726. doi:10.1016/j.vaccine.2022.04.054. PMC 9122779. PMID 35606235. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M (липень 2022). Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 40 (32): 4328—4333. doi:10.1016/j.vaccine.2022.06.032. PMC 9212435. PMID 35738968. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H (липень 2022). Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Vaccine. 40 (31): 4231—4241. doi:10.1016/j.vaccine.2022.05.081. PMC 9167832. PMID 35691872. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)
Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M (червено 2022). Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 40 (27): 3721—3726. doi:10.1016/j.vaccine.2022.04.054. PMC 9122779. PMID 35606235. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M (липень 2022). Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 40 (32): 4328—4333. doi:10.1016/j.vaccine.2022.06.032. PMC 9212435. PMID 35738968. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, Yoshihara K, Iwata-Yoshikawa N, Shiwa-Sudo N, Sakai Y, Shirakura M, Kishida N, Arita T, Suzuki Y, Watanabe S, Asanuma H, Sonoyama T, Suzuki T, Omoto S, Hasegawa H (липень 2022). Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Vaccine. 40 (31): 4231—4241. doi:10.1016/j.vaccine.2022.05.081. PMC 9167832. PMID 35691872. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)
Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M (червено 2022). Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 40 (27): 3721—3726. doi:10.1016/j.vaccine.2022.04.054. PMC 9122779. PMID 35606235. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M (липень 2022). Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 40 (32): 4328—4333. doi:10.1016/j.vaccine.2022.06.032. PMC 9212435. PMID 35738968. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults. jrct.niph.go.jp. Japan Registry of Clinical Trials. Процитовано 21 березня 2021. (англ.)
A Phase 2/3 Study of S-268019. jrct.niph.go.jp. Japan Registry of Clinical Trials. Процитовано 20 жовтня 2021. (англ.)